Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Global X MSCI Argentina ETF (ARGT) Price & Performance

AbCellera Biologics IncTrade
Global X MSCI Argentina ETFTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Global X MSCI Argentina ETF — how do they compare? AbCellera Biologics Inc trades at $9.07 (market cap $2.85B), while Global X MSCI Argentina ETF trades at $92.45. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Global X MSCI Argentina ETF nearer its low. Which is the better fit depends on your goals.

ABCLARGT
Market Cap
$2.85B
Sector
HealthBroad Market / Factor
52-Week High
$9.76$102.94
52-Week Low
$2.78$67.55
Enterprise Value
$2.45B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.

The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.

Global X MSCI Argentina ETF

ARGT trades at $92.96, up 0.43% with a bearish technical signal from moving averages. The ETF shows neutral oscillators with RSI at 44.95. Recent Seeking Alpha analysis (June 18, 2026) highlights a 28% upside potential as Argentina's economic reforms progress, with the fund trading at 12.5x earnings below its post-Milei average.

The outlook suggests potential re-rating to 14-18x earnings could yield 12-44% upside, supported by Argentina's improving monetary backdrop. Key risks include country-specific volatility and concentrated holdings in MercadoLibre. Institutional interest is growing with Stanley Druckenmiller's recent position accumulation.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Global X MSCI Argentina ETF

ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.

Read more on ARGT